Skip to main content

Precision Biosciences Inc

DTIL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001357874

No open-market purchases or sales by Precision Biosciences Inc insiders were filed in the last 90 days; 95 institutions reported holding it in 13F filings for Q2 2026, worth $138.9M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Precision Biosciences Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Precision Biosciences Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Precision Biosciences Inc
NameTitleLast reported holdingLast filingFilings, past year
Germano Geno JDirector44,883Jun 5, 20263
Brown MelindaDirector44,346Jun 5, 20263
Buehler KevinDirector49,137Jun 5, 20262
Frankel StanleyDirector40,478Jun 5, 20264
Pire Shari LisaDirector35,028Jun 5, 20262
Kelly John AlexanderChief Financial Officer125,883Jun 3, 20264
Smith J. JeffersonChief Research Officer121,926Jun 3, 20263
Scimeca DarioGeneral Counsel and Secretary56,457Jun 3, 20264
Amoroso MichaelPresident and CEO243,392Jun 3, 20264
Wadsworth Samuel C.Director4,202Jun 6, 20240
List AlanChief Medical Officer4,488May 3, 20240
Barton ShaneVP & Corporate Controller27,502Jun 9, 20230
Jantz DerekChief Scientific Officer4,055,174Jun 9, 20220
Schinazi Raymond FDirector–May 12, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 21, 2022 (view filing)Mar 174 daysKelly John AlexanderChief Financial OfficerPPurchase+16.7K$3.08+$51.4K+85.5%36.2K after
Apr 28, 2022 (view filing)Apr 271 dayList AlanChief Medical OfficerSSale−7.78K$2.10−$16.3K−29.9%18.3K after
Jun 9, 2022 (view filing)Jun 81 dayScimeca DarioGeneral Counsel and SecretarySSale−9.83K$2.06−$20.3K−23.2%32.5K after
Jun 9, 2022 (view filing)Jun 81 dayJantz DerekChief Scientific OfficerSSale−18.8K$2.06−$38.8K−0.5%4.06M after
Jun 24, 2022 (view filing)Jun 222 daysKelly John AlexanderChief Financial OfficerPPurchase+33.8K$1.50+$50.7K+40.3%117.7K after
Sep 26, 2022 (view filing)Sep 22-234 daysKelly John AlexanderChief Financial OfficerPPurchase+45.2K$1.32+$59.7K+38.4%162.9K after2 lots
Oct 18, 2022 (view filing)Oct 171 dayAmoroso MichaelPresident and CEOSSale−11.0K$1.32−$14.5K−45.5%13.2K after
Mar 7, 2023 (view filing)Mar 61 dayList AlanChief Medical OfficerSSale−9.47K$1.07−$10.1K−19.9%38.2K after
Mar 7, 2023 (view filing)Mar 61 dayScimeca DarioGeneral Counsel and SecretarySSale−12.2K$1.07−$13.0K−19.6%50.1K after
Mar 21, 2023 (view filing)Mar 174 daysKelly John AlexanderChief Financial OfficerPPurchase+20.0K$0.86+$17.2K+8.9%245.6K after
Mar 23, 2023 (view filing)Mar 221 dayAmoroso MichaelPresident and CEOSSale−47.0K$0.82−$38.5K−40.6%68.7K after10b5-1
Apr 28, 2023 (view filing)Apr 271 dayList AlanChief Medical OfficerSSale−7.77K$0.79−$6.14K−12.1%56.5K after10b5-1
Jun 9, 2023 (view filing)Jun 81 dayScimeca DarioGeneral Counsel and SecretarySSale−13.4K$0.75−$10.0K−16.3%68.5K after10b5-1
Oct 27, 2023 (view filing)4:55 PM ETAug 1870 daysKelly John AlexanderChief Financial OfficerPPurchase+90.0K$0.48+$43.2K+30.7%383.3K afterAmended
Nov 6, 2023 (view filing)5:07 PM ETNov 33 daysAmoroso MichaelPresident and CEOSSale−125.0K$0.40−$50.0K−35.5%227.1K after10b5-1
Nov 6, 2023 (view filing)5:09 PM ETNov 33 daysScimeca DarioGeneral Counsel and SecretarySSale−16.0K$0.40−$6.41K−12.4%113.0K after10b5-1
Jan 23, 2024 (view filing)7:11 PM ETJan 23Same daySmith J. JeffersonChief Research OfficerSSale−28.0K$0.37−$10.4K−1.4%1.99M after
Jan 23, 2024 (view filing)7:13 PM ETJan 221 dayList AlanChief Medical OfficerSSale−21.5K$0.36−$7.75K−18.5%95.0K after10b5-1
Jan 23, 2024 (view filing)7:15 PM ETJan 221 dayScimeca DarioGeneral Counsel and SecretarySSale−21.3K$0.36−$7.66K−12.4%151.0K after10b5-1
Jan 23, 2024 (view filing)7:17 PM ETJan 221 dayAmoroso MichaelPresident and CEOSSale−137.4K$0.36−$49.5K−27.8%356.4K after10b5-1
Apr 30, 2024 (view filing)Apr 30Same dayList AlanChief Medical OfficerSSale−238$10.03−$2.39K−5.9%3.80K after
May 3, 2024 (view filing)May 21 dayAmoroso MichaelPresident and CEOSSale−1.53K$10.32−$15.7K−10.0%13.8K after
May 3, 2024 (view filing)May 21 dayList AlanChief Medical OfficerSSale−290$10.32−$2.99K−6.1%4.49K after
May 3, 2024 (view filing)May 21 daySmith J. JeffersonChief Research OfficerSSale−154$10.32−$1.59K−0.2%67.6K after
May 3, 2024 (view filing)May 21 dayScimeca DarioGeneral Counsel and SecretarySSale−272$10.32−$2.81K−4.6%5.68K after10b5-1
May 3, 2024 (view filing)May 12 daysScimeca DarioGeneral Counsel and SecretarySSale−918$0.00$0–919 afterDerivative10b5-1
Jun 11, 2024 (view filing)Jun 101 daySmith J. JeffersonChief Research OfficerSSale−50$11.79−$589.5−0.1%68.6K after
Jun 11, 2024 (view filing)Jun 101 dayScimeca DarioGeneral Counsel and SecretarySSale−93$11.79−$1.10K−1.4%6.72K after10b5-1
Nov 5, 2024 (view filing)Nov 41 dayAmoroso MichaelPresident and CEOSSale−3.01K$8.19−$24.7K−9.5%28.5K after
Nov 5, 2024 (view filing)Nov 41 dayScimeca DarioGeneral Counsel and SecretarySSale−588$8.19−$4.82K−6.9%7.97K after10b5-1
Nov 21, 2024 (view filing)Nov 21Same dayKelly John AlexanderChief Financial OfficerPPurchase+3.00K$6.76+$20.3K+8.6%38.1K after
Dec 30, 2024 (view filing)Dec 264 daysBrown MelindaDirectorPPurchase+3.02K$4.55+$13.7K+71.8%7.22K after
Dec 31, 2024 (view filing)Dec 274 daysKelly John AlexanderChief Financial OfficerPPurchase+2.11K$4.75+$10.0K+5.5%40.2K after
Dec 31, 2024 (view filing)Dec 274 daysBuehler KevinDirectorPPurchase+4.32K$4.88+$21.1K+98.4%8.71K after
Jan 2, 2025 (view filing)Dec 30, 20243 daysGermano Geno JDirectorPPurchase+3.60K$4.49+$16.2K+85.8%7.81K after
Jan 22, 2025 (view filing)Jan 22Same daySmith J. JeffersonChief Research OfficerSSale−10.3K$4.79−$49.3K−10.5%87.4K after10b5-1
Jan 22, 2025 (view filing)Jan 211 dayAmoroso MichaelPresident and CEOSSale−36.8K$4.67−$172.0K−25.6%107.1K after10b5-1
Jan 22, 2025 (view filing)Jan 22Same dayScimeca DarioGeneral Counsel and SecretarySSale−8.93K$4.79−$42.8K−26.8%24.4K after10b5-1
Mar 5, 2025 (view filing)Mar 41 daySmith J. JeffersonChief Research OfficerSSale−154$4.91−$756.14−0.2%87.8K after10b5-1
Mar 5, 2025 (view filing)Mar 41 dayScimeca DarioGeneral Counsel and SecretarySSale−272$4.91−$1.34K−1.1%25.0K after10b5-1
Mar 25, 2025 (view filing)Mar 241 dayAmoroso MichaelPresident and CEOSSale−964$5.56−$5.36K−0.9%109.5K after10b5-1
Mar 27, 2025 (view filing)Mar 252 daysGermano Geno JDirectorPPurchase+3.25K$5.30+$17.2K+41.6%11.1K after
Mar 28, 2025 (view filing)Mar 262 daysBuehler KevinDirectorPPurchase+4.52K$4.67+$21.1K+51.9%13.2K after
Mar 28, 2025 (view filing)Mar 262 daysBrown MelindaDirectorPPurchase+1.84K$4.75+$8.74K+25.5%9.06K after
Jun 27, 2025 (view filing)Jun 252 daysBuehler KevinDirectorPPurchase+5.08K$4.16+$21.1K+22.0%28.1K after
Jun 27, 2025 (view filing)Jun 252 daysBrown MelindaDirectorPPurchase+1.68K$4.14+$6.96K+8.9%20.6K after
Jul 8, 2025 (view filing)Jul 35 daysKelly John AlexanderChief Financial OfficerSSale−14.8K$4.26−$63.2K−16.8%73.5K after10b5-1
Sep 24, 2025 (view filing)Sep 222 daysBrown MelindaDirectorPPurchase+1.40K$4.89+$6.85K+6.8%22.0K after
Sep 30, 2025 (view filing)Sep 264 daysFrankel StanleyDirectorPPurchase+2.70K$4.97+$13.4K+19.2%16.8K after
Nov 4, 2025 (view filing)Nov 31 dayAmoroso MichaelPresident and CEOSSale−3.41K$6.49−$22.1K−2.9%115.6K after10b5-1